CR MEDICAL Reports Interim Results with 21.98% Decline in Net Profit Attributable to Shareholders

Stock News
Yesterday

CR MEDICAL (01515) has announced its interim results for the six months ended June 30, 2026, revealing a challenging period marked by a decrease in profitability despite relatively stable revenue generation.

According to the financial report, the group recorded revenue of RMB 4.479 billion, reflecting a modest year-on-year decline of 1.02%. However, profit attributable to shareholders amounted to RMB 265 million, representing a significant drop of 21.98% compared to the corresponding period last year. Basic earnings per share stood at RMB 0.21, and the board has proposed an interim dividend of RMB 0.05 per share.

In terms of operational performance, the hospital business segment achieved turnover of RMB 4.317 billion during the reporting period, marking a year-on-year increase of 1.4%. The outpatient and emergency department visits grew by 5.2%, while inpatient admissions saw a modest rise of 0.3%. Notably, the average revenue per outpatient and emergency visit declined by 6.1%, whereas the average revenue per inpatient visit increased by 3.1%.

As of June 30, 2026, the group managed and operated a total of 90 medical institutions across 10 provinces and cities in China. During the reporting period, the group's self-owned hospitals handled approximately 5.37 million outpatient and emergency visits and 270,000 inpatient admissions, representing year-on-year growth of 5.2% and 0.3%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10